

Revisiting Epstein-Barr Virus as an Under-studied Causative Agent for Nasopharyngeal Carcinoma: An integrated Movement Against Unprecedented Respiratory-associated Pandemic

☀️ One under-considered yet a key player in Carcinogenesis : ☀️

EBV is one causative bioagent to carcinogenesis and infects almost 95% population



HOST-PATHOGEN is POORLY DEFINED ☀️

Ika Nurlaila, PhD

ika.nurlaila@brin.go.id

Early career research scientist

At present running cancer immunology and immunotherapy projects (two consecutive years)



Since pandemic is highly associated with respiratory-associated diseases that the host fail to overcome

Nasopharyngeal carcinoma cohort

Strategic Plan

Open to Advance the Development

Aim	<p>To investigate host-pathogen interaction in EBV-positive NCP and EBV-positive healthy donors with family links to the included patients.</p> <p>To investigate if there is a defect in immunity which causes the counteraction against the viral antigen is impaired: antigen processing machinery may be an excellent start</p> <p>To see/measure correlation of EBV infection in anticancer drug resistance or responsiveness as this might add more volume to health burden (economic burden)</p>
Primary Technique	<p>Bulk sequencing on cohort of EBV-positive Nasopharyngeal Carcinoma (will be provided by the Department of Medical Hematology-Oncology, Dr. Ciptomangunkusumo Hospital)</p> <p>Epitope sequencing</p>
Additional technique	<p>HPLC/MS, CryoEM</p>
Outcome	<p>DEG feature (comparison of the patients, non-cancer donor with family link, HD)</p> <p>Peptide specific (spanning LAMP)-T as well as B cell</p> <p>Novel prototype of anti-EBV vaccine</p>

